Aortic disease: Losartan versus atenolol in the Marfan aorta-how to treat?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

1. Marfan on the Move.Journal of the American Heart Association · 2017
   Article
2. Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall.Cellular and molecular life sciences : CMLS · 2017
   Review
3. Cardiovascular Management of Adults with Marfan Syndrome.European cardiology · 2016
   Review
4. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.Arteriosclerosis, thrombosis, and vascular biology · 2016
   Article

Corrections and comments

• Comment on
  Marfan Sartan: a randomized, double-blind, placebo-controlled trial.2015

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as